The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. iii Current treatment options have limited efficacy in terms of weight loss or are often associated with adverse events. “We

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

New Drug Approvals

JUNE 26, 2025

1] PATENT US 217370 [link] [link] [link] Medical uses Acoltremon was approved for medical use in the United States in May 2025, for the treatment of signs and symptoms associated with dry eye disease. [2] Ma S, Gisselmann G, Vogt-Eisele AK, Doerner JF, Hatt H (October 2008). 2008 Oct;21(4):370-8. 29 May 2025. 21 (4): 370–378.

FDA 48

FDA Small Molecule Clinical Trials FDA Approval 48

The Pharma Data

DECEMBER 4, 2020

from the Boston Medical Center, and colleagues used data from the Behavioral Risk Factor Surveillance System (2008 to 2018) to assess the impact of Medicaid expansion on linkage to care, self-maintenance, and treatment among low-income adults with diabetes. In the early period, Medicaid expansion led to a 5.3-percentage

Treatment 52

Treatment Research 52

New Drug Approvals

SEPTEMBER 8, 2024

5 On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis, 6 which is a condition associated with aberrant bile acid metabolism. Retrieved 5 September 2024. ^ Billin AN (October 2008). Seladelpar cas 851528-79-5 C 21 H 23 F 3 O 5 S, 444.47 2007 Jul 15;17(14):3855-9.

FDA 62

FDA Licensing Licensing FDA Approval 62

Broad Institute

AUGUST 27, 2024

Notable successes were the development of the PARP inhibitor Zejula, which changed the treatment paradigm for women diagnosed with ovarian cancer, and the approval of dostarlimab in first line endometrial cancer and its development in first line MSI-H rectal cancer. Prior to its acquisition by GSK for $5.1

Science 52

Science Regulations Production Drug Development 52

Broad Institute

AUGUST 25, 2023

Thanks to the generous funding from Ted and Vada Stanley, and the collaborative environment of the Broad Institute, researchers at the Stanley Center have made strides toward understanding severe psychiatric disease with the goal of contributing to new understandings of pathogenesis, the identification of biomarkers, and above all, new treatments.

Research 52

Research DNA International Disease 52

The Pharma Data

DECEMBER 8, 2020

The analysis focused on 125 rap songs issued by North American artists, drawn from Top 25 lists issued in 1998, 2003, 2008, 2013 and 2018. “Kanye’s ‘808s & Heartbreak’ album in 2008 was groundbreaking in its emotional openness, and really appears to have paved the way for a new generation of artists.”

Doctors 52

Doctors Treatment Research 52

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. J Immunol 180(9):6044-6053 (2008). A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas. Lamb L, Pereboeva L, Youngblood S, et al.

Therapies 105

Therapies Engineering Molecular Biology Science 105

The Pharma Data

NOVEMBER 25, 2020

. “People with MS tend to have urinary symptoms and treatments that themselves can be risk factors for bladder cancer,” he said. They found that between 2008 and 2017, the chance of developing bladder cancer was 72% higher among MS patients. Nor did the study account for MS treatments, which might affect cancer risk.

Doctors 52

Doctors Treatment Hospitals Research 52

The Pharma Data

JUNE 28, 2021

Earlier this year, Xarelto was approved in Canada, the EU including UK, Japan and Switzerland for the treatment of VTE and prevention of VTE recurrence in children and adolescents aged less than 18 years after at least 5 days of initial parenteral anticoagulation treatment. EINSTEIN-Jr.

FDA 52

FDA Clinical Trials Treatment Therapies 52

Drug Target Review

FEBRUARY 7, 2024

The gene expression ‘transcriptome’ from the cell type we studied has a p-value that is better than this by a factor of 500,000x. How do the findings of the research reveal the potential treatments options for COVID-19, particularly in terms of managing excessive inflammation and targeting specific enzymes?

RNA 69

RNA Virus Immune Response Engineering 69

Conversations in Drug Development Trends

APRIL 5, 2024

Observed annually on the last day of February since 2008, Rare Disease Day has grown into a global movement for raising awareness, promoting research, and advocating for improved access to rare disease treatments and support services. For others, this rare day is aptly the day we honor rare disease communities.

Disease 52

Disease Clinical Trials Trials Treatment 52

The Pharma Data

DECEMBER 17, 2020

The conference highlighted recent advances in the risk, diagnosis, treatment, and prevention of breast cancer , with presentations focusing on emerging treatments in hard-to-treat patient populations, including patients with metastatic breast cancer. We’re moving away from a one-size-fits-all treatment approach.”

Treatment 52

Treatment Therapies Clinical Trials Disease 52

DrugBank

JUNE 27, 2023

The general notion is that patients should be viewed individually, rather than strictly as members of some larger general population, and that their specific genetic background, environment, and lifestyle choices should be considered throughout drug development to the point of treatment and continuing patient care.

Disease 98

Disease Treatment Drugs Clinical Trials 98

Metabolite Tales Blog

APRIL 4, 2023

3 Metabolism differences at steady state Adagrasib, Mirati’s irreversible KRASG12C inhibitor for treatment of non-small cell lung cancer is mainly metabolised by CYP3A4. 2008 Mar;153 Suppl 1(Suppl 1):S82-9. Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.

Small Molecule 52

Small Molecule FDA Approval FDA Drugs 52

The Pharma Data

AUGUST 9, 2020

In the HIBISCUS I induction study, in people without prior anti-tumour necrosis factor (anti-TNF) treatment, etrolizumab met the primary endpoint. In contrast, the HIBISCUS II induction study, which also included people without prior anti-TNF treatment, did not meet its primary endpoint.

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52

Drug Target Review

SEPTEMBER 26, 2023

This will be achieved by inducing a seizurogenic phenotype using a known seizurogenic compound, and then determining if these changes are reduced by application epilepsy treatments. 2008 Mar;153 Suppl 2(Suppl 2):S1-209. 26 Outside of drug safety, we also plan to adapt our model to anti-epileptic drug discovery. cited 2023 Jun 15].

Drugs 111

Drugs FDA Disease Animal Testing 111

The Pharma Data

NOVEMBER 25, 2020

A new website takeironseriously.com has been launched to educate individuals and healthcare professionals on the symptoms of iron deficiency, demonstrate the ease of diagnosis and encourage people to seek treatment to protect their health. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review.

International 52

International Pharmaceuticals Disease Pharmaceutical Companies 52

Metabolite Tales Blog

JULY 5, 2023

Current macrocycles in clinical use generally focus on treatment of infectious diseases, cancer and auto-immune disorders. However, more de novo designed molecules in this “beyond the Rule of 5 chemical space” have emerged, with the first in this class, plerixafor , approved in oncology in 2008.

Drugs 52

Drugs Metabolic Stability FDA Approval Treatment 52

Metabolite Tales Blog

JULY 5, 2023

Current macrocycles in clinical use generally focus on treatment of infectious diseases, cancer and auto-immune disorders. 2] However, more de novo designed molecules in this “beyond the Rule of 5 chemical space” have emerged, with the first in this class, plerixafor , approved in oncology in 2008.

Drugs 52

Drugs Metabolic Stability FDA Approval Treatment 52

The Pharma Data

JANUARY 25, 2021

She had her second open-heart surgery in February 2008. “The typical treatments didn’t work, and she always took longer to recover.” After two weeks at home, she went into heart failure and spent the next two months in the cardiac ICU. “She never played by the rules,” Lori said.

Doctors 52

Doctors Hospitals Treatment Research 52

The Pharma Data

NOVEMBER 20, 2020

And an AHA advisory in 2008 recommended screening for depression in people with coronary heart disease. ” Medoff said with less stigma these days attached to mental health treatment, better communication can make for better overall health. That is “critical. And this is regardless of whether you have heart disease or not.”

Disease 52

Disease Nurses Research Hospitals 52

The Pharma Data

OCTOBER 15, 2020

John Hospital, researchers compared 649 patients from two cohorts: a recent cohort (2017–2019) from the RECOVER III post-market approval (PMA) study, after the widespread adoption of the best practice of placing Impella pre-PCI, and a cohort from before PMA (2008–2014) when the practice of placing Impella pre-PCI was not yet widely adopted.

Hospitals 52

Hospitals FDA Approval FDA Treatment 52

NIH Director's Blog: Drug Development

JUNE 14, 2016

Scott and colleagues focused on six genes that encode potential drug targets licensed or in development by GlaxoSmithKline for the treatment of obesity or diabetes. December 2008. [2] References : [1] Guidance for industry diabetes mellitus—Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.

Drugs 52

Drugs Disease Drug Development Clinical Trials 52

The Pharma Data

DECEMBER 17, 2020

Most recently, Cadavid served as senior vice president and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases. She joined VMS BioMarketing in 2008 and has served as its president and CEO since 2011.

Small Molecule 52

Small Molecule Clinical Development Engineering Pharmaceuticals 52

FDA Law Blog: Biosimilars

FEBRUARY 27, 2024

FDA also approved two NDAs on the same first day for micafungin (MYCAMINE)—NDA 021506 for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation, and NDA 021754 for the treatment of esophageal candidiasis. In that case, the NDA sponsor applied for two PTEs based on these approvals—one for either U.S.

FDA Approval 59

FDA Approval FDA Production Therapies 59

New Drug Approvals

JANUARY 13, 2023

Indications Forasartan is indicated for the treatment of hypertension [6] and, similar to other ARBs, it protects the kidneys from kidney blood vessel damage caused by increased kidney blood pressure by blocking renin–angiotensin system activation. [7] January 2008). Ram CV (August 2008). 39 (Database issue): D1035-41.

Pharmacokinetics 52

Pharmacokinetics Drugs Production Research 52

The Pharma Data

NOVEMBER 5, 2020

has been appointed to the additional role of president and will oversee the growth of the company’s technology portfolio for the treatment of ischemic and hemorrhagic stroke. Prior to joining Navitor, Hughes served as president and CSO of Zafgen and previously led Zafgen as CEO from 2008 to 2017. Schijns, a former professor at N.C.

Pharmaceuticals 40

Pharmaceuticals Analytical Chemistry Small Molecule Therapies 40

Agency IQ

JUNE 2, 2023

Proposal for a regulation Initiative entry End-of-life vehicles – revision of EU rules Adoption is planned for second quarter of 2023 This initiative proposes improved collection, treatment, and recycling of end-of-life vehicles (ELVs).

Regulations 40

Regulations Production International Marketing 40

Agency IQ

AUGUST 30, 2024

CAD and CMRD) are coming to a close this month (CLP is the acronym for Regulation (EC) No 1272/2008 on classification, labeling and packaging of substances and mixtures; CAD and CMRD stand for chemical agents directive and carcinogens, mutagens, reprotoxic substances directive, respectively).

Regulations 40

Regulations Production Government Packaging 40

Agency IQ

APRIL 19, 2024

Bugin is also the deputy director of operations in the CDER Office of New Drugs (OND), and has been with the agency since 2008 with the exception of a short stint to serve as Chief of Staff for Operation Warp Speed during the pandemic. treatment effect), derived from the observed data and a prior probability distribution for the parameter.

Clinical Trials 40

Clinical Trials Trials Science FDA 40

Codon

APRIL 9, 2024

In response to the precipitous rise in incidence, governments on both sides of the Pacific began a systematized search for antimalarial treatments. Over the course of 12 years, the Walter Reed Army Institute of Research (WRAIR) screened more than 250,000 compounds in search of an efficacious treatment. Nobody had an answer.

Drugs 141

Drugs Science Research Doctors 141

Drug Target Review

JANUARY 15, 2024

1 Lung transplantation is the only viable treatment option, yet finding suitable lung donors is difficult. 2008 October 27 [2024 January 5]; 4:435-459. Although tobacco smoking is the primary cause of this inhalation injury, many other environmental and occupational exposures contribute to the pathology of COPD. Cell Stem Cell.

Immune Response 113

Immune Response Disease Science Therapies 113

Agency IQ

OCTOBER 6, 2023

In a first, FDA tackles treatments for stimulant use disorder A new draft guidance from the FDA gives developers a roadmap to advance the development of novel therapies to address stimulant use disorders. SAMSHA published an “ evidence-based resource guide ” on substance use disorder treatment in June 2020.

FDA 40

FDA Treatment Production Trials 40

PLOS: DNA Science

OCTOBER 5, 2023

When a suspicious, routine mammogram catapults you through the maze of more scans, biopsies, and then a zillion treatment choices, you have to become expert in interpreting the nuances of a pathology report – or find someone who is. That was 20 years ago, before the targeted treatments that are greatly extending survival today.

DNA 96

DNA Treatment Science Doctors 96

Codon

OCTOBER 22, 2024

However, I think caution is warranted when drawing sweeping conclusions from these studies because they were each conducted over only a decade (between 1998 and 2008) in just two medical journals (the British Medical Journal and The Annals of Emergency Medicine.) These numbers are quite low and do not inspire confidence.

Science 122

Science Research Government Cell Biology 122

Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. Journal of virology 82 , 5887-5911 (2008). Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. Grimm D, et al.

Engineering 105

Engineering Virus Therapies Immune Response 105